AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 13000
- Registration Number
- NCT06742736
- Locations
- 🇺🇸
AstraZeneca, Wilmington, Delaware, United States
A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.
Phase 1
Recruiting
- Conditions
- Dyslipidemia
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT06742853
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT06742762
- Locations
- 🇺🇸
Research Site, Orlando, Florida, United States
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Phase 3
Recruiting
- Conditions
- Chronic Kidney Disease and Hypertension
- Interventions
- Drug: Baxdrostat/dapagliflozinDrug: Placebo/dapagliflozin
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5000
- Registration Number
- NCT06742723
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Study to Evaluate the Pharmacokinetics and Pharmacodynamics of AZD4604 Given Via the Turbuhaler® Device in Adults With Mild Asthma.
Phase 1
Recruiting
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT06732882
- Locations
- 🇬🇧
Research Site, Wythenshawe, United Kingdom
Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer
Recruiting
- Conditions
- Breast Cancer
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 135
- Registration Number
- NCT06727227
- Locations
- 🇸🇮
Research Site, Maribor, Slovenia
UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
Recruiting
- Conditions
- Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT06726720
- Locations
- 🇫🇷
Research Site, Villeurbanne, France
A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Early COPD Outcomes in Chinese Population
Recruiting
- Conditions
- COPD
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 850
- Registration Number
- NCT06724848
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
EVOLVE Study: The Real-life Clinical Practice With Tezepelumab in Greece
Recruiting
- Conditions
- Asthma
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT06724575
- Locations
- 🇬🇷
Research Site, Crete, Greece
🇬🇷Research Site, Thessaloniki, Greece
A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults
Phase 1
Recruiting
- Conditions
- Healthy Participants
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 105
- Registration Number
- NCT06723756
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath